Literature DB >> 33350772

Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A protocol for systematic review and meta analysis.

Pengxian Tao1,2, Lei Gao1,2, Haiyuan Li1,2, Bofang Wang1,2, Xuemei Li1,2, Ying Zhang3, Hao Chen1.   

Abstract

BACKGROUND: Previous studies have showed that the high expression of urokinase plasminogen activator (uPA) in pathology and serology is closely related to the progression of hepatocellular carcinoma (HCC). However, there are no systematic reviews for these evidence, and the association between uPA and HCC is still not completely understood. Therefore, we will undertake a systematic review of the literature to summarize previous evidence regarding this topic, in order to clarify the prognostic significance of uPA in HCC. METHODS AND ANALYSIS: Studies comparing the HCC patients with high and low expression of uPA on the clinicopathological features and the prognosis are eligible for this review. Outcomes include all endpoints about survival and clinicopathological features. Prospective or retrospective primary studies which published in English will be included. Four databases of Medline, EMBASE, Web of Science, and the Cochrane Library will be systematically searched from their inception to Mar 2021 to retrieve relevant studies. Reference lists of included studies will be manually reviewed and grey literatures will be identified by Google Scholar. Two reviewers will independently screen the records and extract the information and data of the included studies. The Newcastle-Ottawa Scale will be used to assess the quality of included studies. Hazard ratio and 95% confidence interval will be pooled to assess the association between uPA expression and the prognosis. Pooled odds ratio and 95% confidence interval will be used for other outcomes. Heterogeneity will be assessed using the Cochrane Q test and I2 statistic, and a subgroup analysis will be performed if necessary. Grades of Recommendation, Assessment, Development and Evaluation method will be applied to assess the certainty of evidence. ETHICS AND DISSEMINATION: This protocol required information extracted from previously published articles. So, there is no ethical problem in this study. We plan to publish our findings in peer-reviewed journals and relevant conference proceedings. SYSTEMATIC REVIEW REGISTRATION: This study has been registered with the International Prospective Register of Systematic Reviews database (no.CRD42020150340).
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33350772      PMCID: PMC7769352          DOI: 10.1097/MD.0000000000023841

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  26 in total

1.  Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients.

Authors:  Alfonso Iorio; Frederick A Spencer; Maicon Falavigna; Carolina Alba; Eddie Lang; Bernard Burnand; Tom McGinn; Jill Hayden; Katrina Williams; Beverly Shea; Robert Wolff; Ton Kujpers; Pablo Perel; Per Olav Vandvik; Paul Glasziou; Holger Schunemann; Gordon Guyatt
Journal:  BMJ       Date:  2015-03-16

2.  Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers.

Authors:  Volker R Jacobs; Doris Augustin; Arthur Wischnik; Marion Kiechle; Cornelia Hoess; Oliver Steinkohl; Brigitte Rack; Thomas Kapitza; Peter Krase
Journal:  Breast       Date:  2016-06-23       Impact factor: 4.380

3.  Hepatocellular carcinoma surveillance: an open question.

Authors:  Maurizio Biselli; Francesca Garuti; Andrea Neri
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

4.  Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.

Authors:  Tipattaraporn Panich; Khajornsak Tragoolpua; Supansa Pata; Chatchai Tayapiwatana; Nutjeera Intasai
Journal:  Cancer Biother Radiopharm       Date:  2017-01-24       Impact factor: 3.099

5.  Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors:  S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

6.  Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.

Authors:  K S Song; A Lee; J R Choi; O H Kwon
Journal:  Thromb Haemost       Date:  1995-09       Impact factor: 5.249

7.  Evaluation of Different Blood Circulating miRNAs for Hepatocellular Carcinoma Diagnosis.

Authors:  Shutong Wang; Jian Wu; Shunli Shen; Zhijun Geng; Yunzhi Ling; Baogang Peng
Journal:  J Nanosci Nanotechnol       Date:  2020-03-01

8.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.

Authors:  Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  BMJ       Date:  2015-01-02

9.  Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.

Authors:  Akiko Sumi; Jun Akiba; Sachiko Ogasawara; Masamichi Nakayama; Yoriko Nomura; Makiko Yasumoto; Sakiko Sanada; Osamu Nakashima; Toshi Abe; Hirohisa Yano
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

10.  Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.

Authors:  Chao-Bin Yeh; Yung-Luen Yu; Chiao-Wen Lin; Hui-Ling Chiou; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  BMC Complement Altern Med       Date:  2014-04-30       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.